Executive Summary: CVR deployment reaches $35 billion across Q1-Q3 2025 transactions Contingent Value Rights (CVRs) have become integral to biotech M&A structuring, with deployment across $35 billion in transaction value through Q3 2025. Data indicates CVR inclusion in 29% of life sciences acquisitions, representing a structural shift

In a high-interest-rate environment (U.S. Fed Funds ~5.25–5.50% in 2024), traditional biotech funding has pulled back sharply (VC investment in life sciences fell ~60% from 2021 peaks) while royalty financing has surged ~45% annually. The appeal is clear: royalty deals offer non-dilutive capital

The AI drug discovery sector achieved its first major clinical validation in 2025 with Insilico Medicine's rentosertib becoming the first fully AI-discovered and designed drug to demonstrate positive Phase IIa results, marking a significant development for the industry. This breakthrough, published in Nature Medicine in June 2025,

Biotech dealmaking surged this week, from Pfizer’s $7.3 billion obesity acquisition to a run of licensing, royalty financings, and venture rounds. Disclosed upfronts exceeded $6 billion, with total potential deal values over $9 billion. The week highlights two trends: Big Pharma securing pipelines in obesity, CNS, and AI-

Overview Milestone payments are contingent fees in pharmaceutical and biotech deals that become due when a product achieves specific goals. They are ubiquitous in licensing and collaboration agreements (and even in M&A via so-called earn-outs or CVRs) because they help bridge valuation gaps between partners. Rather

Introduction and Company Overview Revolution Medicines (NASDAQ: RVMD) is a late-stage oncology biotech focused on targeting the RAS oncogene family, historically considered "undruggable." The company has developed a pipeline of RAS(ON) inhibitors – small molecules that bind RAS in its active, GTP-bound state – designed to suppress

Executive Summary Breakout Ventures is a San Francisco-based venture capital firm specializing in life sciences and "deep tech" investments. Spun out of a philanthropic seed program in 2016, Breakout Ventures has quickly carved a niche funding early-stage companies where biology, chemistry and technology converge. This report

Current Market Dynamics and Transaction Volume The biotech venture debt market underwent substantial transformation following the Silicon Valley Bank collapse in March 2023. Prior to its failure, SVB serviced approximately 50% of early-stage U.S. biotechnology companies, representing a concentration risk that materialized catastrophically. The subsequent market restructuring resulted

The biopharma sector in 2025 is navigating a difficult funding landscape. Public markets have cooled off after the boom of 2020–2021, leaving many biotech companies cash-hungry in what observers dub a "biotech winter." In this environment, Private Investments in Public Equity (PIPEs) have emerged as a

1. Historical Examples of Disease-Linked Bonds Pandemic Bonds (World Bank PEF) The most prominent example is the World Bank's Pandemic Emergency Financing Facility (PEF) bonds, launched in June 2017 in response to the devastating 2014–16 West African Ebola outbreak. This was the first time pandemic risk